. 2015 Mar 1;15(5):1–61.

Table 3:

Natural History Model Parameters Used in the Economic Model

Model Parameter	Base-Case Value	Sensitivity Analysis Range	Reference
Treatment Eligibility
Proportion eligible for treatment
Hysterectomy	1.0000	Fixed	(27)
Myomectomy	1.0000	Fixed	(27)
UAE	0.9000	0.8–1	(27)
MRgHIFU	0.3500	0.25–0.45	(27)
Treatment Efficacy^a
Probability of symptom relief
Hysterectomy	1.0000	Fixed	(27)
Myomectomy	0.7990^b	0.65–0.95	(31, 32)
UAE	0.8520^b	0.6–1	(27, 31–33)
MRgHIFU	0.8940^b	0.75–1	(27, 34, 35)
Probability of symptom recurrence in 6–month period
Hysterectomy	0	Fixed	(27)
Myomectomy	0.0500	+/− 20%	(27)
UAE	0.0300	+/− 20%	(27)
MRgHIFU	0.0600	+/− 20%	(27)
Treatment Safety^a
Probability of major complications^c
Hysterectomy	0.0200	+/− 20%	(27)
Myomectomy	0.0210^b	+/− 20%	(27, 31, 36)
UAE	0.0340^b	+/− 20%	(27, 31, 33)
MRgHIFU	0.0130^b	+/− 20%	(27, 35, 37)
Probability of procedure-related death
Hysterectomy	0.0020	+/− 20%	(27)
Myomectomy	0.0020	+/− 20%	(27)
UAE	0.0015	+/− 20%	(27)
MRgHIFU	0		(27)

Abbreviations: MRgHIFU, magnetic resonance-guided high-intensity focused ultrasound; UAE, uterine artery embolization.

Efficacy and safety with second- and third-line treatment are assumed to be the same as for the corresponding first-line treatment.

Weighted average (weighted by number of subjects in each study).

Major complications include infection, hemorrhage requiring infusion, unintended major surgery, life-threatening event, and rehospitalization for hysterectomy, (38) febrile morbidity for myomectomy, (39) pulmonary embolus for UAE, (40) and deep vein thrombosis for MRgHIFU. (35)